Novartis' Mayzent Receives Health Canada's Approval for Secondary Progressive Multiple Sclerosis with Active Disease
Shots:
- The approval is based on P-III EXPAND study assessing Mayzent vs PBO in 1651 patients with SPMS from 31 countries including 47 participants in Canada with a mean age of 48yrs.- living with MS for ~16yrs.- >50% had a median EDDS score of 6.0 and relied on a walking aid
- The P-III EXPAND study result demonstrated a reduction in diseases progression- including impact on physical disability
- Mayzent is an S1P receptor modulator and the first oral therapy approved for SPMS with active disease. The approval of Mayzent is a tribute to Novartis’s relentless commitment to reimagining MS treatment
Click here to read full press release/ article | Ref: Novartis | Image: StraitTimes
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com